 Ocuphire Pharma Inc NASDAQ: OCUP stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mesylate designed to reverse pharmacologically induced mydriasis dilation of pupil for eye exams. 